相似文献
1
A clinical trial of gene therapy for chronic pain.
Pain Med. 2009 Oct;10(7):1325-30. doi: 10.1111/j.1526-4637.2009.00720.x.
2
A human trial of HSV-mediated gene transfer for the treatment of chronic pain.
Gene Ther. 2009 Apr;16(4):455-60. doi: 10.1038/gt.2009.17. Epub 2009 Feb 26.
3
Gene therapy for pain: results of a phase I clinical trial.
Ann Neurol. 2011 Aug;70(2):207-12. doi: 10.1002/ana.22446. Epub 2011 Jul 27.
4
Herpes vector-mediated gene transfer in the treatment of chronic pain.
Mol Ther. 2009 Jan;17(1):13-8. doi: 10.1038/mt.2008.213. Epub 2008 Oct 7.
5
HSV vector-mediated modification of primary nociceptor afferents: an approach to inhibit chronic pain.
Gene Ther. 2009 Apr;16(4):493-501. doi: 10.1038/gt.2009.24.
6
Gene therapy for the treatment of chronic peripheral nervous system pain.
Neurobiol Dis. 2012 Nov;48(2):255-70. doi: 10.1016/j.nbd.2012.05.005. Epub 2012 Jun 2.
7
Gene therapy of bladder pain with herpes simplex virus (HSV) vectors expressing preproenkephalin (PPE).
Urology. 2001 Jun;57(6 Suppl 1):116. doi: 10.1016/s0090-4295(01)01060-3.
8
Development of HSV-mediated gene transfer for the treatment of chronic pain.
Exp Neurol. 2003 Nov;184 Suppl 1:S25-9. doi: 10.1016/s0014-4886(03)00357-1.
9
Gene therapy for pancreatitis pain.
Gene Ther. 2009 Apr;16(4):483-92. doi: 10.1038/gt.2009.27. Epub 2009 Mar 5.
10
Nasal application of HSV encoding human preproenkephalin blocks craniofacial pain in a rat model of traumatic brain injury.
Gene Ther. 2017 Aug;24(8):482-486. doi: 10.1038/gt.2017.55. Epub 2017 Jul 20.
引用本文的文献
1
Strategies for delivering therapeutics across the blood-brain barrier.
Nat Rev Drug Discov. 2021 May;20(5):362-383. doi: 10.1038/s41573-021-00139-y. Epub 2021 Mar 1.
2
Low GRK2 Underlies Hyperalgesic Priming by Glial Cell-Derived Neurotrophic Factor.
Front Pharmacol. 2018 Jun 5;9:592. doi: 10.3389/fphar.2018.00592. eCollection 2018.
3
Novel Pharmacological Nonopioid Therapies in Chronic Pain.
Curr Pain Headache Rep. 2018 Apr 3;22(4):31. doi: 10.1007/s11916-018-0674-8.
4
Gene delivery strategies to promote spinal cord repair.
Biomark Insights. 2015 Apr 9;10(Suppl 1):11-29. doi: 10.4137/BMI.S20063. eCollection 2015.
5
Pharmacogenomic considerations in opioid analgesia.
Pharmgenomics Pers Med. 2012;5:73-87. doi: 10.2147/PGPM.S23422. Epub 2012 Aug 23.
6
Early in life bladder inflammation alters opioid peptide content in the spinal cord and bladder of adult female rats.
J Urol. 2013 Jan;189(1):352-8. doi: 10.1016/j.juro.2012.08.190. Epub 2012 Nov 19.
7
Viral vectors and delivery strategies for CNS gene therapy.
Ther Deliv. 2010 Oct;1(4):517-34. doi: 10.4155/tde.10.50.
8
Gene therapy: a potential approach for cancer pain.
Pain Res Treat. 2011;2011:987597. doi: 10.1155/2011/987597. Epub 2011 Jun 9.
9
Development of viral vectors for gene therapy for chronic pain.
Pain Res Treat. 2011;2011:968218. doi: 10.1155/2011/968218. Epub 2011 Apr 7.
10
Pain in amyotrophic lateral sclerosis: a neglected aspect of disease.
Neurol Res Int. 2011;2011:403808. doi: 10.1155/2011/403808. Epub 2011 May 3.
本文引用的文献
1
A human trial of HSV-mediated gene transfer for the treatment of chronic pain.
Gene Ther. 2009 Apr;16(4):455-60. doi: 10.1038/gt.2009.17. Epub 2009 Feb 26.
2
Protein kinase C epsilon contributes to basal and sensitizing responses of TRPV1 to capsaicin in rat dorsal root ganglion neurons.
Eur J Neurosci. 2008 Oct;28(7):1241-54. doi: 10.1111/j.1460-9568.2008.06438.x.
3
Continuous delta-opioid receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7) levels through activation of protein kinase C in painful diabetic neuropathy.
J Neurosci. 2008 Jun 25;28(26):6652-8. doi: 10.1523/JNEUROSCI.5530-07.2008.
4
Gene therapy directed at the neuroimmune component of chronic pain with particular attention to the role of TNF alpha.
Neurosci Lett. 2008 Jun 6;437(3):209-13. doi: 10.1016/j.neulet.2008.03.049. Epub 2008 Mar 22.
5
Applications of gene therapy to the treatment of chronic pain.
Curr Gene Ther. 2008 Feb;8(1):42-8. doi: 10.2174/156652308783688527.
6
HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor alpha in spinal cord microglia.
Gene Ther. 2008 Feb;15(3):183-90. doi: 10.1038/sj.gt.3303054. Epub 2007 Nov 22.
7
Gene transfer to interfere with TNFalpha signaling in neuropathic pain.
Gene Ther. 2007 Jul;14(13):1010-6. doi: 10.1038/sj.gt.3302950. Epub 2007 Apr 19.
8
Engineering an endomorphin-2 gene for use in neuropathic pain therapy.
Pain. 2007 Dec 15;133(1-3):29-38. doi: 10.1016/j.pain.2007.02.003. Epub 2007 Mar 28.
9
Tumor necrosis factor-alpha contributes to below-level neuropathic pain after spinal cord injury.
Ann Neurol. 2006 May;59(5):843-51. doi: 10.1002/ana.20855.
10
HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain.
Mol Pain. 2006 Feb 17;2:6. doi: 10.1186/1744-8069-2-6.
Zotero 插件